KRYSTAL BIOTECH INC (KRYS)
Sector: Health Care
2026 Annual Meeting Analysis
KRYSTAL BIOTECH INC · Meeting: May 15, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class III Directors
Krystal's 3-year stock return of +226% outpaces the peer group median by +144 percentage points, far exceeding the 65-point threshold needed to trigger a concern, so the TSR test does not raise a flag; no overboarding, attendance, or independence issues were identified.
Dr. Mason has served since January 2021 and brings deep gene and cell therapy expertise as the company's Science and Technology Committee chair; the TSR trigger does not apply given Krystal's strong outperformance of both its peer group and XBI (SPDR S&P Biotech ETF), and no other policy concerns were identified.
Both Class III nominees pass all policy screens. Krystal's 3-year stock return of +226% beats the disclosed peer group median by roughly 144 percentage points and beats XBI (SPDR S&P Biotech ETF) by roughly 158 percentage points — well above the 65-point threshold required to trigger a concern for a company with strong positive returns. Neither director is overboarded, attendance was at least 75%, and both bring relevant qualifications. Vote FOR both nominees.
Say on Pay
✓ FORCEO
Krish S. Krishnan
Total Comp
$10,442,485
Prior Support
96%%
The CEO's total pay of approximately $10.4 million is reasonable for a biotechnology company of Krystal's size (~$7.6 billion market cap) that delivered $389 million in product revenue and a 3-year stock return of +226%, dramatically outperforming XBI (SPDR S&P Biotech ETF) by roughly 158 percentage points. Pay structure is heavily weighted toward variable, at-risk compensation — the company reports approximately 85% of the CEO's total pay is variable — satisfying the policy requirement that at least 50-60% be performance-linked. The program received over 96% shareholder support at the prior annual meeting, the company has a formal clawback policy in place, and the pay-for-performance alignment is strong given the company's exceptional stock performance and commercial milestones.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
N/A
Audit Fees
$955,000
Non-Audit Fees
$23,625
Non-audit fees (tax consulting of $23,625) represent only about 2.5% of audit fees ($955,000), well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed so no tenure trigger fires; KPMG is a Big 4 firm appropriate for a $7.6 billion market-cap company; all services were pre-approved by the Audit Committee.
Stockholder Proposals
1 proposal submitted by shareholders
Proposal 4
Approval of the Non-Employee Director Compensation Policy
This proposal asks shareholders to approve a formal non-employee director compensation policy that was developed as part of the settlement of a Delaware lawsuit alleging that prior director pay was excessive; the policy sets 2026 pay at the 50th percentile of a disclosed peer group (annual equity awards of $400,000 per director) and caps future years at the 75th percentile without requiring further shareholder votes through 2030. The settlement structure — which requires both shareholder approval and court approval to become effective, and which excludes director votes from the tally — provides meaningful checks on potential self-dealing. While the board retaining discretion to increase pay up to the 75th percentile without future votes is a modest governance concession, the overall package represents a clear improvement over the prior unconstrained pay practice and is the product of arms-length litigation, making it appropriate to support.
Overall Assessment
The 2026 Krystal Biotech annual meeting presents a straightforward ballot with no significant governance red flags: the company has delivered exceptional shareholder returns over three years (+226% versus +68% for XBI, the SPDR S&P Biotech ETF), executive pay is heavily performance-linked and received 96% shareholder support last year, KPMG's non-audit fees are minimal, and the director compensation policy proposal is supported by a settlement framework that imposes meaningful constraints on future pay. All four proposals merit a FOR vote.
Compensation Peer Group
17 companies disclosed in 2026 proxy filing